Boston Scientific Co. (NYSE:BSX) Shares Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the medical equipment provider’s stock after purchasing an additional 5,000 shares during the period. Boston Scientific comprises about 5.2% of Sivik Global Healthcare LLC’s holdings, making the stock its 3rd largest holding. Sivik Global Healthcare LLC’s holdings in Boston Scientific were worth $9,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Crews Bank & Trust acquired a new stake in Boston Scientific during the 4th quarter worth approximately $85,000. DMC Group LLC lifted its holdings in shares of Boston Scientific by 13.6% during the fourth quarter. DMC Group LLC now owns 7,899 shares of the medical equipment provider’s stock worth $706,000 after purchasing an additional 947 shares during the period. Highland Capital Management LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $4,887,000. Foster Victor Wealth Advisors LLC grew its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Foster Victor Wealth Advisors LLC now owns 196,112 shares of the medical equipment provider’s stock worth $19,348,000 after purchasing an additional 1,517 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Boston Scientific by 13.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 1,922,301 shares of the medical equipment provider’s stock valued at $171,700,000 after purchasing an additional 224,280 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BSX shares. Mizuho raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 27th. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Price Performance

BSX opened at $103.85 on Thursday. The firm’s fifty day moving average price is $92.74 and its two-hundred day moving average price is $85.81. The company has a market capitalization of $153.06 billion, a price-to-earnings ratio of 85.59, a P/E/G ratio of 2.63 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1 year low of $62.63 and a 1 year high of $103.27.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.